Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

1,710

Participants

Timeline

Start Date

February 14, 2019

Primary Completion Date

October 9, 2019

Study Completion Date

October 9, 2019

Conditions
Pneumococcal Disease
Interventions
BIOLOGICAL

20vPnC

20vPnC

BIOLOGICAL

20vPnC

20vPnC

BIOLOGICAL

20vPnC

20vPnC

BIOLOGICAL

13vPnC

Pneumococcal conjugate vaccine

Trial Locations (21)

14609

Rochester Clinical Research, Inc., Rochester

27612

M3 Wake Research, Inc., Raleigh

28401

PMG Research of Wilmington, LLC, Wilmington

30281

Clinical Research Atlanta, Stockbridge

32720

Accel Research Sites - Clinical Research Unit, DeLand

33024

Research Centers of America, LLC, Hollywood

40004

Kentucky Pediatric/Adult Research, Bardstown

57049

Meridian Clinical Research, LLC, Dakota Dunes

67207

Heartland Research Associates, LLC, Wichita

68134

Meridian Clinical Research, LLC, Omaha

68701

Meridian Clinical Research, LLC, Norfolk

78705

Benchmark Research, Austin

84109

J. Lewis Research, Inc. /Foothill Family Clinic, Salt Lake City

84121

J. Lewis Research, Inc. /Foothill Family Clinic South, Salt Lake City

92801

Anaheim Clinical Trials, LLC, Anaheim

95051

Kaiser Permanente Santa Clara, Santa Clara

95119

Kaiser Permanente San Jose, San Jose

95815

Kaiser Permanente Sacramento, Sacramento

95823

Kaiser Permanente South Sacramento, Sacramento

96814

East West Medical Research Institute, Honolulu

02886

Omega Medical Research, Warwick

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03828617 - Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults | Biotech Hunter | Biotech Hunter